Nerve Microvessel Changes in Diabetes are Prevented by Aldose Reductase Inhibition

Timothy J. Benstead and Virgilio E. Sangalang

ABSTRACT: Background: Despite the potential importance of endoneurial microvessel abnormalities in diabetic neuropathy, the pathogenesis of these abnormalities is incompletely understood. We wished to evaluate the effect of experimental diabetes on endoneurial microvessels and determine if an aldose reductase inhibitor alters any of the changes induced by diabetes. Methods: We compared streptozocin diabetic rats with and without aldose reductase inhibitor treatment to non-diabetic rats after 10 months of diabetes. Transverse microvessels from the mid-sciatic level were studied by electron microscopic morphometric evaluation. Results: Microvessel endothelial, pericyte, basement membrane and total mural area were greater in untreated diabetic animals than non-diabetic animals. Aldose reductase inhibitor treated diabetic animals had greater endothelial area and possibly pericyte area but not basement membrane or total mural area. Conclusions: This study demonstrates that endoneurial microvessel abnormalities can be detected in experimental diabetic neuropathy. Microvessel basement membrane thickening will be prevented by an aldose reductase inhibitor. One mechanism by which abnormal polyol pathway activity may contribute to diabetic neuropathy could be through damage to microvessels.


of microangiopathy has been statistically associated with severity of nerve fibre alteration.\textsuperscript{16-18}

To further develop the polyol pathway hypothesis we were interested in evaluating a potential link between polyol pathway disturbance and endoneurial microvessel abnormalities. In particular we wished to determine if aldose reductase inhibition reduces the thickening of any of the microvessel wall components seen in diabetic neuropathy. Aldose reductase activity is found in endothelial cells of microvessels in nerves and other tissues.\textsuperscript{1,19} Aldose reductase inhibition has been shown to prevent basement membrane thickening in experimental diabetic retinopathy.\textsuperscript{20,21} Experimental models of diabetic endoneurial microangiopathy have been infrequently studied\textsuperscript{22} and the effect of pharmacological manipulation has not been reported. In this study we determined that endoneurial microangiopathy can be demonstrated in experimental diabetes and long term use of an aldose reductase inhibitor can prevent some microangiopathic changes.

**Materials and Methods**

Male Sprague-Dawley rats at age 3 months were divided into 3 groups. Two groups had diabetes induced by intraperitoneal injection of streptozocin 50 mg/kg. One group of diabetic animals (n = 4, onset weight 340.3 ± 7.3 g) was not treated. The second diabetic group (n = 6, 347.0 ± 13.2 g) received the aldose reductase inhibitor Statil 25 mg/kg (ICI Pharma) mixed into the daily feed of rat chow from the onset of diabetes. This dose of Statil has been previously demonstrated to inhibit aldose reductase activity in experimental diabetic neuropathy, normalizing nerve sorbitol levels and ameliorating nerve conduction velocity abnormalities in diabetic rats.\textsuperscript{23} The third group of animals did not have diabetes induced and did not receive any medication (n = 6, 343.7 ± 15.7 g). The animals were raised on shavings in polypropylene cages and given unlimited water. Blood glucose and weight were monitored in all 3 groups at regular intervals. Glucose was measured on capillary blood using a glucometer after an overnight fast. Diabetes was defined as animals with blood glucose measurements greater than 17 mmol/L throughout the duration of the study.

At 10 months following induction of diabetes the animals were anaesthetized with sodium pentobarbital 50 mg/kg and the right sciatic nerve was exposed taking care not to damage nerve shavings in polypropylene cages and given unlimited water. The borders of the vessel lumen (LA), outer endothelial border (OEB), pericyte cell body and processes (P) and outer vessel border (OVB) were traced. A programmable digitizing tablet was used to determine the area within the space circumscribed by these borders. The endothelial area (OEB-LA), basement membrane area [OVB − (P + OEB)] and mural area (OVB-LA) were calculated. The number of endothelial nuclei per vessel and pericyte nuclei per vessel were counted.

Values for comparison are expressed as mean ± standard deviation (SD). The mean values compared are the means of the groups which are obtained by averaging the mean values from each animal. To determine if an overall difference in the size of the microvessel wall was present among the groups, the mural area of the 3 groups was compared using ANOVA one way analysis. Two-sampled t-tests for unpaired samples (95 percent confidence limits) were then used to assess separate components of the vessel wall as well as other microvessel features of interest including lumen area, endothelial nuclei per vessel, pericyte nuclei per vessel and total vessel area. Statistical difference was compared between the untreated diabetic and non-diabetic groups, the Statil treated diabetic and non-diabetic groups and the Statil treated diabetic and untreated diabetic groups.

**Results**

All diabetic rats had persistent blood glucose measurements greater than 20 mmol/L. The diabetic rats without Statil developed dense cataracts and with Statil only slight or no cataracts. Weights of animals in the untreated diabetic group (454.5 ± 18.0 gm, p = 0.0005) and Statil treated diabetic group (435.3 ± 60.9, p = 0.0005) were significantly lower at the end of the study than the non-diabetic group (705.0 ± 30.2 gm) consistent with what is anticipated in experimental diabetic neuropathy.\textsuperscript{27} There was no obvious alteration of endoneurial microvessel appearance at light microscopic magnification level. Microvessels examined by electron microscopy were occasionally closed in the diabetic nerves. The microvessel wall gave the appearance of thickening in diabetic nerves which was confirmed by morphometric analysis (Figures 1-3). Using ANOVA the mural area between the 3 groups was different (p < 0.05). There did not appear to be other structural differences of mural
Figure 1: Electron micrograph of endoneurial microvessel from the tibial nerve of a non-diabetic rat. Measurements were made of the vessel lumen (arrow), outer endothelial border (double arrows), pericyte cell body and processes (arrowhead) and outer vessel border (double arrowheads). The size of mural components were calculated from these measurements. Stained with uranyl acetate and lead citrate. Calibration bar = 2.0 μm.

Figure 2: Endoneurial microvessel from a diabetic rat. On average the size of all components of the vessel wall including endothelial cell, pericyte cell and basement membrane were significantly greater than non-diabetic rats. The basement membrane between the endothelial and pericyte cells in this vessel appears thickened. Stained with uranyl acetate and lead citrate. Calibration bar = 2.0 μm.

Figure 3: Endoneurial microvessel from a Statil treated diabetic rat. Mean endothelial cell area was greater in Statil treated diabetic rats than non-diabetic animals and the mean pericyte area was also greater approaching significant levels. The mean basement membrane area measurement for the Statil treated group was not greater than in the non-diabetic group. Stained with uranyl acetate and lead citrate. Calibration bar = 2.0 μm.

Elements in diabetic nerve microvessels. Excess pericyte degeneration or degeneration of endothelial organelles was not seen. Tight junctions between endothelial cells appeared preserved.

Morphometric measurements were made of multiple microvessels from each animal, all obtained from sections at the same transverse level. The mean number of microvessels measured per rat was not different between groups (Table). The microvessel lumen area and total vessel area were largest in the diabetic animals but mean values were not significantly different between groups. As compared to non-diabetic controls all components of the vessel wall in untreated diabetic nerves were increased in size including endothelial area (P = 0.005), pericyte area (P = 0.038), basement membrane area (P = 0.024) and total mural area (P = 0.005). The increased size of wall components ranged from an increase of 31% for pericyte area, 35% for endothelial area and 40% for basement membrane area. In the Statil treated diabetic group the endothelial area was 25% greater than the control group which was significant (P = 0.016). Pericyte area was 25% greater than controls which reached borderline significance (P = 0.051). There was no significant difference in the basement membrane area of Statil treated diabetic nerves and control nerves. The overall mural area of the Statil group was not significantly different than control. The number of endothelial and pericyte nuclei per vessel was not different in either diabetic group compared to controls suggesting that the endothelial and pericyte changes are due to increase in cell size and not cell number.

Comparisons between the Statil treated and untreated diabetic groups demonstrated that for all measurements except basement...
Endoneurial microvessel wall was found including endothelium, of the microvessel wall and the rates of vessel closure are statistically significant. Animals with experimental diabetic neuropathy will demonstrate thickening of mural elements including endothelium, pericytes and basement membrane. Mean total vessel area was 17.2 ± 5.4 μm² and pericyte nuclei/vessel was 0.42 ± 0.18. Mean basement membrane area was 17.2 ± 5.4 μm².

DISCUSSION

The present study demonstrates that endoneurial microvessel abnormalities develop after 10 months of experimental diabetic neuropathy. Experimental diabetic microangiopathy has not been frequently reported. The model used in the current study proved helpful for studying the effect of pharmacological manipulation on diabetic microangiopathy. Due to the potential importance of microvessels in the pathogenesis of diabetic neuropathy, the experimental model of microangiography demonstrated here will be very useful for evaluating future possible treatment strategies.

Endoneurial microvessels in chronic clinical diabetic neuropathy demonstrate thickening of mural elements including endothelial cells, pericytes and basement membrane. This results in increased rates of microvessel closure. The alterations of the microvessel wall and the rates of vessel closure are statistically associated with the severity of nerve fibre change in diabetic neuropathy. The pattern of myelinated fibre damage and loss is consistent with the pattern of an ischemic neuropathy.

The endoneurial microenvironment demonstrates reduced nerve blood flow and decreased oxygen tension in experimental diabetic neuropathy and patients with diabetic neuropathy. Nerve conduction velocity slowing and myelin abnormalities develop in rats reared in a hypoxic environment. Oxygen supplementation of animals with experimental diabetic neuropathy will improve electrophysiologic abnormalities. These morphologic and physiologic data have led to the conclusion that endoneurial microvessel abnormalities may play an important role in the development of diabetic neuropathy.

The pattern of microvessel change in the present experimental model of diabetes correlates well with what is seen in clinical diabetic neuropathy. Thickenings of the three components of the endoneurial microvessel wall was found including endothelium, pericytes and basement membrane. Mean total vessel area was greatest in the diabetic group raising the concern that basement membrane area increase may at least in part reflect the measurement of larger vessels in that group. However, the total vessel area was not significantly different between groups and the method of selecting microvessels for measurement was chosen to avoid bias toward evaluating larger or smaller microvessels in any particular animal. The results should reasonably represent the mean values from each animal making comparisons between groups valid.

Only a few vessels were closed in the experimental model, but it is possible that end stage microvessel abnormalities may require much longer duration diabetes than the 10 months of this study. Statin prevented basement membrane thickening in endoneurial microvessels similar to what has been demonstrated in retinal microvessels in diabetes treated with an aldose reductase inhibitor. Statin may have a beneficial effect in preventing changes in vessel wall structures as the pericyte change in Statin treated animals was of borderline significance. It is not certain what specific effect an alteration of each mural component would have on the vessel function, though oxygen transport, nutrient transport and the blood nerve barrier would be at risk for dysfunction by microvessel changes.

When the oxygen transport function of microvessels is interrupted a number of hypoxic consequences will occur in the nerve. Some of these may occur immediately but delayed secondary effects may develop. It has been shown that capillary closure will directly damage nerve fibres. Experimental occlusion of endoneurial microvessels with microspheres produces a pattern of myelinated fibre alteration similar to what is found in diabetic and other ischemic neuropathies. Ischemia produces marked changes in nerve structures other than myelinated fibres such as the perineurium and the endoneurial microvessel itself. The endothelial cells of the microvessel are particularly susceptible to ischemic damage. This means that once microvesSEL pathology has been initiated a progressively worsening cycle may develop of hypoxic induced microvessel damage, worsened hypoxia and greater microvessel damage.

Microvessel changes could also contribute to development of an ischemic microenvironment through reduced prostacyclin synthesis in endoneurial microvessels leading to increased platelet aggregation, increased microvessel tone and reduced
nerve blood flow. As well, thickened rigid microvessel walls may be incapable of normal squeezing of red blood cells to assist oxygen exchange.\textsuperscript{40,41} Vasodilatation has been reported in acute diabetic neuropathy\textsuperscript{42} and is an early indicator of abnormal vasoreactivity. In this model of chronic diabetic neuropathy lumen area was not altered suggesting that vasodilatation is no longer present at this stage.

Regardless of how and to what extent abnormal microvessels contribute to the development of diabetic neuropathy it has not yet been established how microvessels are altered in the first instance. The present study provides one potential link between microvessel abnormalities and the metabolic disruption of the nerve microenvironment that is set in motion by hyperglycemia. During hyperglycemia the polyol pathway actively converts glucose to sorbitol through the enzyme aldose reduc tase. This metabolic process may be responsible for several complications of diabetes.\textsuperscript{43,44} Increased polyol activity in experimental diabetic neuropathy leads to depletion of tissue myo-inositol,\textsuperscript{6,7} though in human diabetic neuropathy reduced myo-inositol is not always found.\textsuperscript{45} Voltage clamp studies show sodium channel activity at the node of Ranvier is impaired\textsuperscript{46} by abnormal sodium potassium ATPase activity that can be attributed to myo-inositol reduction.\textsuperscript{8} Abnormalities of nodal function could slow nerve conduction velocity which is the first electrophysiologic abnormality found in experimental diabetic neuropathy. As well, axoglial dysjunction present in diabetic neuropathy may be the result of the metabolic abnormalities at the node that occur in early diabetes.\textsuperscript{10} This structural nodal abnormality may explain why the nerve conduction abnormalities in established diabetic neuropathy are poorly reversible despite correction of the hyperglycemia.

The current study shows that microvessels are also affected by abnormal polyol pathway activity. An important link between aldose reductase activity and microvessel alteration may result from abnormalities in nitric oxide metabolism due to increased polyol production. Nitric oxide is a potent vasodilator.\textsuperscript{42} Aldose reductase activity competes with nitric oxide synthetase for NADPH\textsuperscript{47} which may decrease production of this vasodilator over time. However, in the acute stages of diabetes an increased NADH/NAD\textsuperscript{+} ratio promotes increased nitric oxide production.\textsuperscript{42} These changes in vasoreactivity may contribute to chronic morphologic microvessel abnormalities in diabetic neuropathy. The morphologic abnormalities of microvessels similar to myelinated fibre alterations may be poorly reversible in established diabetic neuropathy.

In addition to polyol pathway abnormalities, other metabolic factors may play a role in the development of diabetic neuropathy. Non-enzymatic glycation of proteins contributes to vessel abnormalities through increased protein cross linking in the vessel wall.\textsuperscript{48,49} This effect appears to be largely independent of aldose reductase activity\textsuperscript{49} though polyol pathway abnormalities may indirectly promote glycation by increasing fructose levels. As well, nitric oxide may be linked to glycation as aminoguanidine inhibits the production of both.\textsuperscript{50} Further work is necessary to determine how these various factors interact to produce microvessel abnormalities in diabetic neuropathy.

It is possible that microvessel abnormalities in diabetic neuropathy develop secondary to the metabolic disturbance but do not have any pathogenic role in the development of myelinated fibre alteration. Similar microvessel changes have been reported in inherited neuropathies which are not felt to have any ischemic pathogenic mechanism.\textsuperscript{51} Metabolic abnormalities could damage axons and Schwann cells directly\textsuperscript{9-11,52,53} with microvessels as innocent bystanders being affected by the metabolic changes that lead more directly to fibre damage. However, the results of many studies to date support the presence of some ischemic process affecting diabetic nerve. The strong link demonstrated between microvessel changes and the progression of neuropathy makes the possibility that microvessels are not at all important to the development of diabetic neuropathy unlikely to be entirely correct. It would seem more likely that microangiopathy contributes to diabetic neuropathy as one component of a multifactorial process that includes hypoxia and other direct metabolic effects on myelinated fibres.

In experimental diabetic neuropathy the morphologic changes of myelinated fibres are not as striking as those in well established clinical diabetic neuropathy. Changes in the region of the node of Ranvier,\textsuperscript{9-11} axonal shrinkage\textsuperscript{52} and Schwann cell injury\textsuperscript{53} occur in experimental and clinical diabetic neuropathy but it is unclear how the mild morphologic changes of experimental diabetic neuropathy relate to the severe multifocal fibre damage and loss in clinical diabetic neuropathy. Short term experimental diabetic neuropathy likely does not completely model what occurs in long term clinical diabetic neuropathy. The current study demonstrates that vascular changes can be detected after 10 months of experimental diabetic neuropathy. A much longer period of time may be required for these vascular changes to advance to the point where they will produce sufficient ischemia in the nerve to lead to multifocal fibre loss. Therefore, the morphologic alterations of microvessels in experimental diabetic neuropathy of 10 months duration may be as important a marker of nerve damage from diabetes as the early structural changes in myelinated fibres. Experimental microvessel changes may also be an important target for assessment of therapeutic intervention when the aim of intervention is to prevent late stage ischemic myelinated fibre alteration.

\section*{Acknowledgement}

The authors thank Marina Payson and Debbie Sheppard for their expert technical and secretarial assistance. Support for this project was received from ICI Pharma.

\section*{References}
